Evotec Nominates Dr. Wolfgang Hofmann to Supervisory Board, Reaches Agreement with MAK Capital

Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced the nomination of Dr. Wolfgang Hofmann for election as an independent member of the Supervisory Board at the company’s upcoming Annual General Meeting (AGM) on June 11, 2026. The AGM agenda also includes the previously announced nomination of Dieter Weinand as Chairman of the Supervisory Board and a proposal to expand the board from six to seven members. These moves are part of Evotec’s ongoing transformation to enhance oversight and governance capabilities.

Following constructive discussions, Evotec has entered into a cooperation agreement with MAK Capital Fund LP (“MAK Capital”), a key shareholder. Under the terms, MAK Capital has agreed to customary voting and cooperation commitments. This agreement reflects Evotec’s commitment to open shareholder dialogue and long-term value creation.

Prof. Dr. Iris Low-Friedrich, Chairwoman of Evotec’s Supervisory Board, stated: “We are pleased to nominate Wolfgang for election at the upcoming AGM. His appointment would contribute oversight and governance capabilities through additional industry, scientific and governance expertise, complementing our existing Board structure as we continue to implement our transformation plans to grow shareholder value. The agreement reached reflects Evotec’s commitment to constructive shareholder engagement, supporting the long‑term success of the Company.”

Michael A. Kaufman, Chief Executive Officer of MAK Capital, said: “We appreciate the constructive dialogue and welcome Wolfgang’s nomination to the Supervisory Board. We look forward to continuing our collaboration with the Supervisory Board and Management Board to support Evotec's ongoing transformation.”

Evotec is a life science company pioneering drug discovery and development by integrating breakthrough science with AI-driven innovation. The company works with all Top 20 Pharma companies and over 800 biotechs, offering services from standalone projects to fully integrated R&D partnerships. More information is available at www.evotec.com and on LinkedIn.